Since JAK inhibitors, such as baricitinib and JTE-052, utilized in the treatment of AD, potentially interfere with the JAK/STAT3 axis [16,17,18], we expected that baricitinib and JTE-052 might enhance the upregulation of FLG and LOR expression induced by tapinarof treatment. The gene discussed is STAT3; the disease is Alzheimer disease.